Loading...
Loading...
Browse all stories on DeepNewz
VisitOpenAI Develops GPT-4b-Micro AI Model with Retro Biosciences to Enhance Longevity Research, Achieving 50 Times Greater Effectiveness
Jan 17, 2025, 04:00 PM
OpenAI has developed a new AI model, named GPT-4b-micro, in collaboration with Retro Biosciences, a longevity startup funded by Sam Altman. This model is designed to enhance the reprogramming of cells by providing suggestions on how to re-engineer Yamanaka factors, which are crucial for cellular reprogramming. The collaboration aims to extend human life, with the model reportedly allowing researchers to modify two of the Yamanaka factors to achieve over 50 times greater effectiveness. The initiative reflects OpenAI's broader commitment to advancing longevity science through innovative bioengineering solutions.
View original story
Markets
Yes • 50%
No • 50%
Official announcements from OpenAI or Retro Biosciences
No • 50%
Yes • 50%
Official publications or press releases from OpenAI
No • 50%
Yes • 50%
Funding announcements from Retro Biosciences or financial news outlets
No • 50%
Yes • 50%
Peer-reviewed scientific journals or major scientific news outlets
No • 50%
Yes • 50%
Official announcements from OpenAI or Retro Biosciences
Yes • 50%
No • 50%
Press releases or financial news outlets covering Retro Biosciences
Juvenescence • 25%
Unity Biotechnology • 25%
Calico Labs • 25%
Other • 25%
Official announcements from OpenAI
Drug discovery • 25%
Genetic modification • 25%
Cellular reprogramming • 25%
Other • 25%
Research publications or official statements from OpenAI or Retro Biosciences
Other • 25%
Increased lifespan • 25%
Improved cellular health • 25%
Reduced disease incidence • 25%
Research papers or official statements from OpenAI or Retro Biosciences
Organ regeneration • 25%
Other • 25%
Neural enhancement • 25%
Genetic modification • 25%
OpenAI official announcements or major tech news outlets
Cellular rejuvenation • 25%
Other • 25%
Anti-aging treatments • 25%
Disease prevention • 25%
Scientific publications or press releases detailing applications
Johnson & Johnson • 25%
Novartis • 25%
Other • 25%
Pfizer • 25%
Official licensing announcements from companies